BCEIE › News › KIMS

M&A

Krishna Institute of Medical Sciences: Amalgamation/Merger

Krishna Institute of Medical Sciences (KIMS) filed a disclosure titled "Amalgamation/Merger". The company is valued at about ₹31,104 crore.

BCEIE News Desk · Published 4 Nov 2026, 08:47 pm IST · Filing received 4 Nov 2026, 08:31 pm IST

What happened

Krishna Institute of Medical Sciences (KIMS) filed a disclosure with the exchanges on 4 November 2026 at 08:31 PM titled "Amalgamation/Merger".

Company snapshot

Krishna Institute of Medical Sciences is a mid-cap company in the Healthcare sector, with a market value of about ₹31,104 crore.

The stock last traded at ₹740.6, against a 52-week range of ₹575.8–₹858 (13.7% below the high).

Before this filing the shares had moved −0.8% over the month and −8.9% over three months. Average daily turnover over the last 20 sessions was about ₹28.54 crore.

Promoters held 32.50% at the end of Q1 FY27; 10.26% of promoter shares were pledged. Foreign institutions owned 14.74% and domestic institutions 34.43%.

Quarterly results (consolidated, ₹ crore)
QuarterRevenueNet profitEPS (₹)
Q1 FY2687278.61.96
Q2 FY2696167.11.67
Q3 FY2699853.41.33
Q4 FY261,07542.51.06
Q1 FY271,18041.51.04

What history shows

BCEIE's records show 7 previous m&a filings from the company since May 2026.

After those filings, the stock gained 0.5% on average the next trading day and was up 0.3% on average after five days (7 filings with price data).

Across 156 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +1.0% over five days; 60% of them rose the next day.

Market-wide, 2,343 m&a filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 49% rising.

Past reactions describe what happened before; they are not a forecast.

Earlier filings of this kind
DateFilingNext day5 days
29 Oct 2026The Company ahs acquired 5.82% stake in Ushahkal Abhinav Specialty…+2.6%—
29 Oct 2026The Company ahs entered into definitive agreements for acquiring 51%…+2.6%—
6 Oct 2026M&A−0.9%−0.1%
6 Oct 2026Intimation u/r 30-acquistion of upto 51 % stake in Insignia−0.9%−0.1%
6 Oct 2026M&A−0.9%−0.1%

What to watch

  • Regulatory approvals, completion of the deal and its effect on revenue and margins.
  • 4 November 2026: Board meeting — Financial Results.

In the news

Recent coverage elsewhere (links open the original publisher):

Source

Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.

More on Krishna Institute of Medical Sciences Limited